J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.
Right arrow Articles by Marcus, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.
Right arrow Articles by Marcus, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin

JC Lin, MK Ito, SN Stolley, AP Morreale, and DB Marcus

Forty-six adult patients maintained on warfarin therapy were converted from pravastatin to simvastatin. Mean international normalized ratio (INR) significantly increased from 2.42 to 2.74, p = 0.002. Although warfarin doses were reduced in 7 patients and increased in 4 patients following the post-conversion INR measurements, the pre- and postconversion median weekly warfarin dose of all 46 patients did not differ significantly. The number of patients with an INR > 3.0 increased significantly from 6 to 16 following the conversion. There was no report of unusual episodes of bleeding. The results indicate that antihyperlipidemic therapy can be changed safely from pravastatin to simvastatin in patients who are taking warfarin concomitantly. Additional anticoagulation monitoring is not necessary in institutions where patients are followed in formal anticoagulation clinics.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
R. Plakogiannis and R. Ginzburg
Possible Amiodarone Warfarin Interaction: A Reemphasis on a Potentially Dangerous Drug Drug Interaction
Journal of Pharmacy Practice, December 1, 2007; 20(6): 469 - 473.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
T. Westergren, P. Johansson, and E. Molden
Probable Warfarin-Simvastatin Interaction
Ann. Pharmacother., July 1, 2007; 41(7): 1292 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. G. Simonson, P. D. Martin, P. D. Mitchell, K. Lasseter, G. Gibson, and D. W. Schneck
Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics
J. Clin. Pharmacol., August 1, 2005; 45(8): 927 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. Holbrook, J. A. Pereira, R. Labiris, H. McDonald, J. D. Douketis, M. Crowther, and P. S. Wells
Systematic Overview of Warfarin and Its Drug and Food Interactions
Arch Intern Med, May 23, 2005; 165(10): 1095 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
A. Lodwick
State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 208 - 215.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology